Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma  by El Moety, Amr Aly Abd & El Moety, Hoda Abd
Alexandria Journal of Medicine (2011) 47, 31–35Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
www.sciencedirect.comORIGINAL ARTICLEEvaluation of nitric oxide as a novel diagnostic marker
for hepatocellular carcinomaAmr Aly Abd El Moety a, Hoda Abd El Moety b,*a Hepatobillary Unit, Faculty of Medicine, Medical Research Institute, Alexandria University, Egypt
b Chemical Pathology, Medical Research Institute, Alexandria University, EgyptReceived 5 December 2010; accepted 26 February 2011
Available online 26 May 2011*
E
20
Pr
Pe
M
doKEYWORDS
NO;
AFP;
CLD;
HCCCorresponding author. Tel.
-mail address: hoda_aly2002
90-5068 ª 2011 Alexandr
oduction and hosting by Els
er review under responsibilit
edicine.
i:10.1016/j.ajme.2011.04.001
Production and h: +2 012
@yahoo
ia Univ
evier B.V
y of Ale
osting by EAbstract Introduction: Liver cancer is the sixth most common cancer worldwide. HCC is the most
common primary tumor of the liver. The National Comprehensive Cancer Network (NCCN) clin-
ical practice guidelines for treatment of hepatobiliary cancers propose surveillance for the early
detection of HCC by liver ultrasonography every 3–6 months and evaluation of AFP. AFP
>200 ng/ml is considered diagnostic for HCC, although fewer than half of patients of HCC may
generate levels that are high, so that the speciﬁcity of AFP is close to 100% but the sensitivity is
45%. Nitrite/Nitrate is a stable end product of nitric oxide increase in patients with HCC.
Aim: It was to evaluate nitric oxide as a novel diagnostic marker for hepatocellular carcinoma.
Methods: Eighty patients and 15 normal individuals enrolled in the study: Group (1) 15 normal
individuals. Group (2) 30 patients with chronic liver disease without HCC. Group (3) 50 patients
with HCC. History taking, clinical examination, (detection of liver masses, ascites, spleen size,
and grade of encepathalopathy), and Child-pugh scoring. Laboratory investigation: (AlT, AST, bil-2242854.
.com (H.A. El Moety).
ersity Faculty of Medicine.
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32 A.A.A. El Moety, H.A. El Moetyirubin, albumin, prothrombin, GGT, platelet count, AFP, nitric oxide, HBs-Ag, and HCV-Ab).
Abdominal ultrasonography and spiral CT.
Results: The median level of nitric oxide was signiﬁcantly higher in Group (3) (170 lmol/l) than in
Group (2) (56 lmol/l) than in Group (1) (22 lmol/l), with a sensitivity of (68%) and speciﬁcity of
(90%) at a cutoff level of 110 lmol/l and area under the curve of (0.810).While AFP, at a cutoff
level of 200 ng/ml had a sensitivity of (52%), speciﬁcity of (100%) and area under the curve
(0.855). Indeed nitric oxide was high in 42% of AFP-negative HCC patients.
Conclusion: Nitric oxide is a novel diagnostic marker for hepatocellular carcinoma, the simulta-
neous determination of serum nitric oxide and AFP gave signiﬁcant improvement in detection of
HCC patients compared to that of AFP alone.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
All rights reserved.Table 1 Clinical and radiologic characteristics of Group (1)
HCC patients.
Characters N %
Child class grade
A 16 32.0
B 25 50.0
C 9 18.0
Vascular invasion
Yes 16 32.0
No 34 68.0
Spleen enlargement
Yes 26 52.0
No 24 48.0
Ascites
Tense 2 4.0
Moderate 4 8.0
Mild 10 20.0
No 34 68.0
edema
Yes 14 28.0
No 36 72.0
Jaundice
Yes 14 28.0
No 36 72.0
CT classic features
Yes 49 98.0
No 1 2.0
Total 50 100.01. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancer with an incidence of 4–5/100,000 in Western countries
compared with 120/100,000 in Asia and Africa. HCC is one of
the leading causes world wide of cancer mortality due to late
diagnosis.1 Chronic infection with hepatitis B virus (HBV) and
hepatitis C virus (HCV) has been involved in about 80%of cases
world wide of HCC.2 Alfa-feto protein (AFP) is a glycoprotein
formed initially within the yolk sac and later in the liver and gas-
trointestinal tract of the fetus. Serum values of about 70,000 lg/l
are found in neonates, decreasing to the normal value of less
than 10 lg/l within 9–12 months. AFP had a limited value for
the early detection of HCC because about one-third of HCC pa-
tients are presentedwith normal levels.2Higher values can be de-
tected in liver cell regeneration, thus a continuos increase inAFP
values arouses suspicion: a value of more than 100 lg/l is highly
suspicious for HCC. There is only a moderate correlation be-
tween AFP and respective tumor size and doubling time. Serum
AFPmarker has low sensitivity of about 39–64%and high spec-
iﬁcity is between 76%and 91%.AFP values in the normal range
exclude HCC in 90–95%.3–6
The two major features of the natural history of HCV infec-
tion are viral persistence and hepatic damage. Nitric oxide
(NO) is one of the most versatile mediators in control of viral
infections, being the earliest host antiviral response.7 NO acts
as a pro-apoptotic inducer in some cell types or as antiapopto-
tic modulator in other cell types including hepatocytes.8 Also,
it was found that in HCV infected patients there is an en-
hanced inducible nitric oxide synthetase (iNOS) expression,
implying excessive NO formation that positively correlates
with viral load and hepatic inﬂammation.9–11 The most strik-
ing feature of hepatitis C is its marked tendency toward chro-
nicity. NO may impair antiviral response by suppressing type 1
helper T-cell response.12 Also, NO enhances viral escape muta-
tions thus allowing viral persistence.12
NO contributes to viral persistence by means of its anti-
apoptotic effect in hepatocytes8 and HCV increases liver cell
survival by preventing apoptosis through activation of NF-
jB signaling pathway.13 The upregulated INOS gene in
chronic HCV infection leads to oxidative stress and reactive
NO species (RNOS) such as peroxynitrite and nitrogen oxide
leads to cytotoxicity and DNA damage. There is preliminary
data that the non structural HCV protein NS5A and the core
protein are able to induce INOS gene expression and that
HCV and NO interact in a synergistic manner to deliver a po-
tent oncogenic signal to infected hepatocytes.142. Methods
The study included 80 patients and 15 normal subjects. They
were grouped as follows: Group (1) 50 patients with hepatocel-
lular carcinoma. Group (2) 30 patients with chronic hepatitis
C. Group (3) 15 normal subjects. Complete history taking,
clinical examination stressing on (liver and spleen size, ascites,
jaundice, Encepathalopathy, and liver masses). Laboratory
testing after overnight fasting (CBP,15 ALT, AST,16,17 BIL,
Albumin, HBS Ag,18 HCV AB,19 and alpha-fetoprotein20)
and nitric oxide.21 Child pugh score.22 Abdominal ultrasound
for detecting for hepatic lesions.23 Triphasic CT for diagnosis
of focal hepatic lesions as hepatocellular carcinoma with the
characteristic pattern.24 Statistical analyses were performed
using The SPSS soft ware.25
The qualitative variables are presented as number and per-
centages. The quantitative variables are presented as
mean ± standard deviation and median (interquartile range)
Figure 1 Box plot presentation of nitric oxide (NO) among
studied groups.
 
Tests Area under the curve P 
NO( mol/L) 
AFP(ng/ml) 
0.81 
0.855 
<0.001 
<0.001 
Figure 2 ROC curve for the relation between NO and AFP
among patients.
Table 2 Laboratory data of different studied groups.
Group (1) HCC
cases
Group (2) chronic
liver disease
Group (3)
control
Kruskal Wallis test
Value p
NO (lmol/L)
Mean ± SD 495.66 ± 625.72 66.90 ± 43.75 22.2 ± 2.04
Median (IQR) 170 (759.25) 56 (23.25) 22 (5) 50.905* <0.001
AFP (ng/L) Z# p
Mean ± SD 5339,65 ± 25646.35 5.95 ± 4.36
Median (IQR) 220.50 (986.25) 4.80 (3.63) 5.289* <0.001
AST (U/L)
Mean ± SD 73.59 ± 44.94 48.10 ± 28.49 19.40 ± 6.43
Median (IQR) 64 (71) 47 (33.50) 20 (12) 28.812 <0.001
ALT (U/L)
Mean ± SD 41.44 ± 33.12 40.23 ± 21.74 17.47 ± 10.10
Median (IQR) 29.50 (37) 39.50 (27.50) 14 (8) 15.102* 0.001
GGT (U/L)
Mean ± SD 115.82 ± 120.55 39.07 ± 11.31 23.33 ± 8.04
Median (IQR) 75.50 (111.50) 38.50 (13.75) 28 (16) 36.457* <0.001
Albumin (gm/dl)
Mean ± SD 2.93 ± 0.59 3.81 ± 0.55 3.99 ± 0.29
Median (IQR)
Total bilirubin (mg/dl)
2.84 (0.75) 3.85 (0.83) 3.90 (0.20) 43.882* <0.001
Mean ± SD 2.16 ± 2.11 1.16 ± 0.47 0.54 ± 0.17
Median (IQR) 1.50 (2.12) 1 (0.75) 0.50 (0.20) 31.443* <0.001
Platelets/cmm
Mean ± SD 192,140 ± 104 037 270,500 ± 819 62.46 290,666 ± 382 59.76
Median (IQR) 204,500 (189 250) 255,000 (142,500) 300,000 (700,00) 15.523* <0.001
Z#, Mann–Whitney test.
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box plot. Non parametric testes are used namely the Kruskal
Wallis and Mann Whitney tests. Accuracy of the tests (NO
and AFP) is determined by plotting the ROC curve for the
quantitative values and calculation of sensitivities, speciﬁcities,
and predictive values for its categories. The 5% level of signif-
icance is chosen.3. Results
Results, Table 1 shows the clinical and radiographic character-
istics in Group (1) HCC patients. 50% of cases were Child B,
32% were Child A and 18% were Child C. The classic wash in/
Table 3 Sensitivity, speciﬁcity, positive and negative predicitive value for AFP among patients in the two groups.
Sensitivity = 52% Total Group (2)
Chronic liver disease
Group (1)
HCC pateints
AFP
(ng/ml)
Speciﬁcity=100% 26 0 26 >200
+ve predicitive value (100%) 54 30 24 < 200
Table 4 Sensitivity, speciﬁcity, positive and negative predictive value of nitric oxide (NO) in studied patients groups.
Sensitivity = 68% Total Group (2) chronic liver disease Group (1) HCC patients Nitric oxide (NO) (mol/L)
Speciﬁcity = 90% 37 3 34 >110.65
Positive predictive value = 91.9% 43 27 16 <110.65
Negative predictive value = 62.8% 80 30 50 Total
34 A.A.A. El Moety, H.A. El Moetywashout pattern of HCC was present in 98% of cases. Major
vascular invasion was present in 32% of cases. (Table 2) The
median of (NO) was statistically signiﬁcantly higher in Group
(1) HCC (170 lmol/l) than in Group (2) (56 lmol/l) than in
Group (3) (22 lmol/l), where p< 0.001 (Table 2). The median
of AFP was signiﬁcantly higher in Group (1) HCC patients
(220.5 ng/ml) than in Group (2) patients (4.8 ng/ml) and
p< 0.001. The median level of AST was signiﬁcantly higher
in Group (1) (64 U/l) than in Group (2) (47 U/l) than in Group
(3) (20 U/l). The median of ALT was signiﬁcantly higher in
Groups (1) and (2) (29.5 and 39.5 U/l) than in Group (3)
(14 U/l). The median level of (GGT) was signiﬁcantly higher
in Group (1) (75.5 U/l) than in Group (2) (38.5 U/l) than in
Group (3) (28 U/l). The median level of serum albumin was
signiﬁcantly lower in Group (1) (2.84 gm/dl) than in Group
(2) (3.85 gm/dl) than in Group (3) (3.90 gm/dl). The median
level of serum bilirubin was signiﬁcantly higher in Group (1)
(1.5 mg/dl) than in Group (2) (1 mg/dl) than in Group (3)
(0.5 mg/dl) (Fig. 1). The median level of platelet count was sig-
niﬁcantly lower in Group (1) (204,500/cmm) than in Group (2)
(255,000/cmm) than in Group (3) (300,000/cmm). (Fig. 2): The
ROC for simultaneous determination of (AFP) and (NO)
showed an area under ROC curve of (0.855) and (0.81), respec-
tively. Table 3: serum AFP at a cut off of 200 ng/ml, had a sen-
sitivity of (52%), speciﬁcity of (100%), positive predictive
value of (100%) and a negative predictive value of (55.6%).
Table 4: serum (NO) at a cut off of (110.65 lmol/l) had a sen-
sitivity of (68%), speciﬁcity of (90%), positive predictive value
of (91.9%) and negative predictive value of (62.8%). Box plot
presentation of nitric oxide among studied groups showed that
the median value of NO in HCC was signiﬁcantly higher com-
pared to chronic liver disease and control group by the Krus-
kal–Wallis test (p< 0.001).
4. Disscussion
Identiﬁcation of early HCC which is potentially amenable to
aggressive intervention and improved survival is the rationale
behind screening for HCC. An effective screening program,
however, requires certain criteria to be successful, including
the following: a common disease with substantial mortality,
an identiﬁable target group, acceptable tests with high sensitiv-
ity and speciﬁcity, and available treatment.26 Bolondi et al.27demonstrated a median survival of 30 months in patients
whose HCC was detected by surveillance versus 15 months in
those discovered by chance. Other studies have been less con-
vincing.28 Regardless, it has become common practice among
hepatologists to apply one of several surveillance methods to
their high-risk patients.29 Surveillance intervals for HCC are
based on a balance between the tumor doubling time and the
cost of the screening tests. Doubling time of HCC ranges from
1 to 19 months with a median of 4–6 months.30 Most study
protocols conduct screening every 6 months. Diagnostic tools
commonly used include the serum tumor marker alfa-fetopro-
tein (AFP), radiographic imaging, and liver biopsy. Ultra-
sound (US) imaging is commonly applied in addition to, or
in place of, AFP to help detect small hepatic tumors <3 cm.
Its widespread use as a surveillance tool relates to its noninva-
sive nature, high availability, and low cost. In combination
with AFP the PPV can be as high as 94%.31
This study showed that AFP had a sensitivity of 52%, spec-
iﬁcity of 100%, positive predictive value of 100% and a nega-
tive predictive value of 55%. Other studies have shown similar
results with a speciﬁcity of AFP close to 100% but at a cost to
the sensitivity which falls below 45%.32 Another study showed
that using 20 ng/ml as the cut-off point, the sensitivity rose to
78.9% and a speciﬁcity declined to 78.1%.33 For the difference
in results we used the new cut-off diagnostic level of HCC,
which is 200 ng/ml. The positive predictive value (PPV) of
AFP is low, ranging from 9% to 32%.34 The median value
of Nitric oxide was signiﬁcantly higher in HCC Group (1)
patients (170 lmol/l) than in chronic liver disease Group (2)
patients (56 lmol/l) than in normal control Group (3)
(22 lmol/l). The diagnostic performance of nitric oxide in
HCC patients at a cut-off of 110 lmol/l showed that the
sensitivity, speciﬁcity, positive predictive value, and negative
predictive value were (68%, 90%, 91.9%, and 62.8%, respec-
tively) and the combined determination of AFP and nitric
oxide had a sensitivity of 96.2% in determination of HCC
patients. Another study showed similar results where the sen-
sitivity and the speciﬁcity of nitric oxide were (79.5% and
72%) in HCC patients and that nitrite/nitrate was positive in
70% of AFP-negative HCC patients and that the simultaneous
determinations of serum AFP and plasma nitrite/nitrate con-
centrations gave signiﬁcant improvement in HCC detection
compared with AFP alone.35
Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma 355. Conclusion
Nitric oxide is a novel diagnostic marker for hepatocellular
carcinoma and the combined estimation of nitric oxide and
AFP increases the sensitivity of detection and diagnosis of
HCC to 96%.
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